CEO sacking

Quote

Don’t understand what the hype and praise for Lars is all about. He was given a winning hand yet he screwed up big time. So stop all this BS about how great a leader he was.
 


anonymous said:
The failure here is not the recent performance that resulted in the stock decline but rather the decisions that were made years ago that severely underestimated the potential of semaglutide in obesity. Had the company really known what they had, we wouldn’t be in the no-win situation we are in now.

We would’ve had supply from the start. We would gained preference earlier. It would have taken years not months for Zepbound to take over.

Lars himself admitted as much a couple years ago during the peak of our supply issues. We are a diabetes company and we looked at Wegovy and obesity as a nice little add on. We totally underestimated the paradigm shifting potential that GLP-1 had.

Since that decision we made mis-step after mis-step. We thought our way of doing it was the right away and neglected to innovate and all the while Lilly just kept marching on.

You don’t need thousands of reps selling Wegovy. We launched it with a couple hundred. What you needed was supply. Support. Access. Innovation.

But now it’s all too late. Nothing can be done now to change the trajectory of both Ozempic and Wegovy. The best we can do is hope that CagriSema or another asset we’ve acquired can compete.

But again, Lilly is light years ahead of us in pipeline and their next generation meds look better than our own.

Love Novo as a company, but I fear for our future.
Click to expand...
Agree with ya here 100%. I do think pushing Lars out like this was a big mistake as he was much beloved by the employees here. An intelligent and kind leader that you would follow to his next company. Hopefully he can just retire and enjoy life, I'm sure he's built up a bit of a nest egg by now :)
 


anonymous said:
The failure here is not the recent performance that resulted in the stock decline but rather the decisions that were made years ago that severely underestimated the potential of semaglutide in obesity. Had the company really known what they had, we wouldn’t be in the no-win situation we are in now.

We would’ve had supply from the start. We would gained preference earlier. It would have taken years not months for Zepbound to take over.

Lars himself admitted as much a couple years ago during the peak of our supply issues. We are a diabetes company and we looked at Wegovy and obesity as a nice little add on. We totally underestimated the paradigm shifting potential that GLP-1 had.

Since that decision we made mis-step after mis-step. We thought our way of doing it was the right away and neglected to innovate and all the while Lilly just kept marching on.

You don’t need thousands of reps selling Wegovy. We launched it with a couple hundred. What you needed was supply. Support. Access. Innovation.

But now it’s all too late. Nothing can be done now to change the trajectory of both Ozempic and Wegovy. The best we can do is hope that CagriSema or another asset we’ve acquired can compete.

But again, Lilly is light years ahead of us in pipeline and their next generation meds look better than our own.

Love Novo as a company, but I fear for our future.
Click to expand...

There is so much to dissect and poster you nailed it. SOV is so 2002, recall teams of 4 and people tripped over one another. We were on a wave and and it crashed. Look at the number of people we employ, doing what? Not even talking sales reps or field based--look at the people who are in home office- who are they?

Also-Eco teams, innovation regions is not the answer. It is a disaster. Fear for future is real.

The Town Hall call to action-EDGE selling and gain commitment? Competitive selling? Create a positive experience?
 




This disaster is on the leadership team. They wanted to launch Wegovy as quickly as possible only to runout of supply 3 months later. Then we had to sell Saxenda again for another year while supply was built back up. Only supply ran out again. We launched a drug in June of 2021 and didn’t have consistent supply until March 2025. They also completely underestimated the compounded Semaglutide market even though reps kept bringing it up. Lastly, no innovation as we watched LillyDirect take over the cash market. But, blame the reps for not selling enough and cut them while home office is bloated and laughs during conference calls when we had no supply.
 


anonymous said:
The failure here is not the recent performance that resulted in the stock decline but rather the decisions that were made years ago that severely underestimated the potential of semaglutide in obesity. Had the company really known what they had, we wouldn’t be in the no-win situation we are in now.

We would’ve had supply from the start. We would gained preference earlier. It would have taken years not months for Zepbound to take over.

Lars himself admitted as much a couple years ago during the peak of our supply issues. We are a diabetes company and we looked at Wegovy and obesity as a nice little add on. We totally underestimated the paradigm shifting potential that GLP-1 had.

Since that decision we made mis-step after mis-step. We thought our way of doing it was the right away and neglected to innovate and all the while Lilly just kept marching on.

You don’t need thousands of reps selling Wegovy. We launched it with a couple hundred. What you needed was supply. Support. Access. Innovation.

But now it’s all too late. Nothing can be done now to change the trajectory of both Ozempic and Wegovy. The best we can do is hope that CagriSema or another asset we’ve acquired can compete.

But again, Lilly is light years ahead of us in pipeline and their next generation meds look better than our own.

Love Novo as a company, but I fear for our future.
Click to expand...
What will change the trajectory is when The Surpass-CVOT failure for Mounjaro
 


anonymous said:
Helge Lund is the jerk here. He was fired from BP. How is he the one taking decisions?
Click to expand...
Doubtful he took the decision. It’s clear that the majority shareholder decision-maker, Novo Foundation, with Lars Rebien at the helm is unhappy with both the BOD and CEO for himself to step into the BOD immediately. It was blatantly stated that the BOD is lacking pharma knowledge. Helge Lund will be out in 2026.
 


anonymous said:
The failure here is not the recent performance that resulted in the stock decline but rather the decisions that were made years ago that severely underestimated the potential of semaglutide in obesity. Had the company really known what they had, we wouldn’t be in the no-win situation we are in now.

We would’ve had supply from the start. We would gained preference earlier. It would have taken years not months for Zepbound to take over.

Lars himself admitted as much a couple years ago during the peak of our supply issues. We are a diabetes company and we looked at Wegovy and obesity as a nice little add on. We totally underestimated the paradigm shifting potential that GLP-1 had.

Since that decision we made mis-step after mis-step. We thought our way of doing it was the right away and neglected to innovate and all the while Lilly just kept marching on.

You don’t need thousands of reps selling Wegovy. We launched it with a couple hundred. What you needed was supply. Support. Access. Innovation.

But now it’s all too late. Nothing can be done now to change the trajectory of both Ozempic and Wegovy. The best we can do is hope that CagriSema or another asset we’ve acquired can compete.

But again, Lilly is light years ahead of us in pipeline and their next generation meds look better than our own.

Love Novo as a company, but I fear for our future.
Click to expand...
You’re spot on. How could they miscalculate the potential of Wegovy to this extent? You only have to look back on Fenphen and the growth trajectory 25 years ago. The market has only gotten bigger since.

The leadership team was inept and too risk averse to invest in timely capacity scale up. Incredible, since Ozempic was already on the market and had a good safety profile. It’s rumored that Camilla was the only one who saw the potential, but couldn’t get through to Lars F and Henrik Wulff.

We all suffer for it now. And Lars F needed to go.
 


anonymous said:
The failure here is not the recent performance that resulted in the stock decline but rather the decisions that were made years ago that severely underestimated the potential of semaglutide in obesity. Had the company really known what they had, we wouldn’t be in the no-win situation we are in now.

We would’ve had supply from the start. We would gained preference earlier. It would have taken years not months for Zepbound to take over.

Lars himself admitted as much a couple years ago during the peak of our supply issues. We are a diabetes company and we looked at Wegovy and obesity as a nice little add on. We totally underestimated the paradigm shifting potential that GLP-1 had.

Since that decision we made mis-step after mis-step. We thought our way of doing it was the right away and neglected to innovate and all the while Lilly just kept marching on.

You don’t need thousands of reps selling Wegovy. We launched it with a couple hundred. What you needed was supply. Support. Access. Innovation.

But now it’s all too late. Nothing can be done now to change the trajectory of both Ozempic and Wegovy. The best we can do is hope that CagriSema or another asset we’ve acquired can compete.

But again, Lilly is light years ahead of us in pipeline and their next generation meds look better than our own.

Love Novo as a company, but I fear for our future.
Click to expand...
What a quitter and loser mentality! “Nothin can be done now”? You must be the original ultimate DEI hire…A good ole boy!
 


Some here are spot on. Not that nothing can done but the point is Ozempic and Wegovy won’t make it back to accelerated growth the shareholders became use to. And stop with the CVOT failure, if the SURPASS trial meets criteria for CV indication that’s all that matters. Nobody will care about the MACE percentage. And the manufacturing buildup looks like it maybe excess now. Hands down layoffs are coming. Shit, we’re talking about share of voice and positive tension but not using AI yet? So 2007 here. Prepare yourselves, mega change is heading your way, as an investor, it’s a good thing! HCPs will soon have programs that will recommend the best therapy for pts. Why would they need to talk to a rep who knows half the story and is biased? Really?
 


anonymous said:
There is so much to dissect and poster you nailed it. SOV is so 2002, recall teams of 4 and people tripped over one another. We were on a wave and and it crashed. Look at the number of people we employ, doing what? Not even talking sales reps or field based--look at the people who are in home office- who are they?

Also-Eco teams, innovation regions is not the answer. It is a disaster. Fear for future is real.

The Town Hall call to action-EDGE selling and gain commitment? Competitive selling? Create a positive experience?
Click to expand...
Agree to the shift in need to be concerned about a restructure to “evolve” and “change” during 2024. What was needed was an emphasis on letting teams and reps focus on selling against Lilly. Instead, the word “restructure” circulated for almost a year, left all of us focused on nothing more than that. Bad choices and still another indication that Novo is confused on how they want us to be a leader in a market, thus creating followers of all of us to try to, well…catch up.
 


anonymous said:
A lot of the chatter internally is to pare back the salesforce, candidly the ROI has not been great with reps. The corporate chatter is suggesting to pare back on field sales, and redirect that promotional spend to multi channel marketing, and also accepting some margin declination in favor of growing market share through alliances, such as what was announced recently. This seems to make sense, obviously isn’t great news for the salesforce, but the company has a good opportunity to better deploy capital to maintain increase market share..
Click to expand...
You dont work here. You're making too much sense.
 


Novo hasn’t been a leader for sometime. They’ve been reactive with no strategic direction, hence Lars removal. If you were at POA in Jan, Negelle didn’t give a strategy the dumbest of reps couldn’t have made the night before after spending a few hours at the bar. But, they’ll continue the gaslighting and lies until they all get fired or the company really fails…. It’s coming, one, the other or both of those scenarios.
 


anonymous said:
A lot of the chatter internally is to pare back the salesforce, candidly the ROI has not been great with reps. The corporate chatter is suggesting to pare back on field sales, and redirect that promotional spend to multi channel marketing, and also accepting some margin declination in favor of growing market share through alliances, such as what was announced recently. This seems to make sense, obviously isn’t great news for the salesforce, but the company has a good opportunity to better deploy capital to maintain increase market share..
Click to expand...
If, say, RFK Jr put a tail on our salesforce, especially those of us who work near major academic centers, he would splash the news all over his favorite networks that the industry wastes hundreds of millions in salaries and benefits on us.
 




anonymous said:
All Lars Rebien Sorensen ever knew was to take multiple double digit price increases on his drugs because he didn’t have any better ideas for organic growth. The fact that he failed upward to a board position at the foundation is a joke.
Click to expand...
Absolutely!!! Sorensen was a complete failure with minimal strategic mind and now he’s the one shitting in Fruegard. Im not saying F was perfect but the foundation is a complete and utter joke and they are the last group I would depend on to make a decision. So sad people can’t see through it.
 





Write your reply...
Top Bottom
Back
Quote